יחס מחיר לרווח Can-Fite (CANF)

The market trend for Can-Fite BioPharma (CANF) shares on the GURU.Markets platform, where the indicator stands at 0.00, is based on the outsourcing of substance production through Western partners. However, Can-Fite BioPharma (CANF) faces a capital shortage due to expenses associated with the final stages of drug testing. Financial stability relies on exclusive ownership rights to formulas, which grant the company the pricing power to independently determine the cost of tumor therapy.

For a defensive portfolio, fundamental screening requires analyzing the P/E ratio as the relationship between the market price of a share and net income, which determines the cost of one ruble of earnings and the level of overpayment for the asset. In the case of Can-Fite BioPharma (CANF), negative operating leverage and oncology research costs distort this calculation; therefore, changes in the company's P/E value serve as an indicator of market expectations regarding future licensing payments.